No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies-Reference-Cited by-同舟云学术

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

Published:2023-06-28 Issue:5 Volume:3 Page:
ISSN:2690-442X
Container-title:Skin Health and Disease
language:en
Short-container-title:Skin Health and Disease

Author:

Griss Johannes¹^ORCID,Ratzinger Gudrun²^ORCID,Maul Julia‐Tatjana³⁴^ORCID,Weger Wolfgang⁵,Thaçi Diamant⁶^ORCID,Carrascosa José Manuel⁷^ORCID,Jonak Constanze¹^ORCID

Affiliation:

1. Department of Dermatology Medical University of Vienna Vienna Austria

2. Department of Dermatology Medical University of Innsbruck Innsbruck Austria

3. Department of Dermatology University Hospital Zurich Zurich Switzerland

4. Faculty of Medicine University of Zurich Zurich Switzerland

5. Department of Dermatology and Venereology Medical University of Graz Graz Austria

6. Institute and Comprehensive Centre for Inflammation Medicine University of Lübeck Lübeck Germany

7. Department of Dermatology Hospital Universitari Germans Trias i Pujol, IGTP, UAB Badalona Spain

Publisher

Wiley

Subject

Dermatology